Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 6—June 2005
Dispatch

Rifampin-resistant Meningococcal Disease

Jean Rainbow*Comments to Author , Elizabeth Cebelinski*, Joanne Bartkus*, Anita Glennen*, Dave Boxrud*, and Ruth Lynfield*
Author affiliations: *Minnesota Department of Health, Minneapolis, Minnesota, USA

Main Article

Table 2

Antimicrobial drug susceptibilities for meningococcal invasive disease Neisseria meningitidis isolates, Minnesota, USA, 1993–2003*

Antimicrobial drug susceptibility† 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Rifampin 100 100 100 97 100 100 100 100 100 97 100
Ceftriaxone NA NA NA NA NA 100 100 100 100 100 100
Ciprofloxacin NA NA NA NA NA 100 100 100 100 100 100
Chloramphenicol 100 100 100 100 100 100 100 100 100 100 100
Meropenem 100 100 100 100 100 100 100 100 100 100 100
Penicillin 92 100 81 89 92 83 96 95 96 86 93
Trimethoprim-sulfamethoxazole 30 55 74 62 32 42 29 36 52 58 66
No. of cases 27 23 30 40 40 36 56 22 27 36 29
No. of isolates tested (%) 13 (48) 11 (48) 27 (90) 37 (93) 38 (95) 36 (100) 55 (98) 22 (100) 27 (100) 36 (100) 29 (100)

*NA, not available.
†Values for antimicrobial drugs are % of isolates susceptible by broth microdilution.

Main Article

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external